These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 10688628

  • 1. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.
    Toutain PL, Lefebvre HP, Laroute V.
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1094-103. PubMed ID: 10688628
    [Abstract] [Full Text] [Related]

  • 2. Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites.
    Lefebvre HP, Laroute V, Concordet D, Toutain PL.
    J Vet Intern Med; 1999 Mar; 13(1):21-7. PubMed ID: 10052059
    [Abstract] [Full Text] [Related]

  • 3. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach.
    Toutain PL, Lefebvre HP, King JN.
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1087-93. PubMed ID: 10688627
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors.
    Toutain PL, Lefèbvre HP.
    J Vet Pharmacol Ther; 2004 Dec; 27(6):515-25. PubMed ID: 15601445
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
    King JN, Mauron C, Kaiser G.
    Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
    [Abstract] [Full Text] [Related]

  • 6. High serum enalaprilat in chronic renal failure.
    Elung-Jensen T, Heisterberg J, Kamper AL, Sonne J, Strandgaard S, Larsen NE.
    J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):240-5. PubMed ID: 11881130
    [Abstract] [Full Text] [Related]

  • 7. Renal actions of the new angiotensin-converting enzyme inhibitor benazepril hydrochloride.
    Levens NR.
    Arch Int Pharmacodyn Ther; 1988 Dec; 296():131-43. PubMed ID: 2853611
    [Abstract] [Full Text] [Related]

  • 8. Clearance of imidapril, an Angiotensin-converting enzyme inhibitor, during hemodialysis in hypertensive renal failure patients: comparison with quinapril and enalapril.
    Tsuruoka S, Kitoh Y, Kawaguchi A, Sugimoto K, Hayasaka T, Saito T, Fujimura A.
    J Clin Pharmacol; 2007 Feb; 47(2):259-63. PubMed ID: 17244777
    [Abstract] [Full Text] [Related]

  • 9. Plasma concentrations of an angiotensin-converting enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, after repeated administrations of benazepril in dogs with experimental kidney impairment.
    Kitagawa H, Eguchi T, Kitoh K, Ohba Y, Kondo M, Nakano M, Sasaki Y.
    J Vet Med Sci; 2000 Feb; 62(2):179-85. PubMed ID: 10720188
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.
    King JN, Maurer M, Toutain PL.
    J Vet Pharmacol Ther; 2003 Jun; 26(3):213-24. PubMed ID: 12755906
    [Abstract] [Full Text] [Related]

  • 11. Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats.
    King JN, Strehlau G, Wernsing J, Brown SA.
    J Vet Pharmacol Ther; 2002 Oct; 25(5):371-8. PubMed ID: 12423228
    [Abstract] [Full Text] [Related]

  • 12. Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency.
    Giri S, Mahajan SK, Sen R, Sharma A.
    J Assoc Physicians India; 2002 Oct; 50():1245-9. PubMed ID: 12568207
    [Abstract] [Full Text] [Related]

  • 13. The pharmacokinetics of benazepril relative to other ACE inhibitors.
    Gengo FM, Brady E.
    Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV44-50; discussion IV51-5. PubMed ID: 1893642
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.
    King JN, Maurer M, Morrison CA, Mauron C, Kaiser G.
    Xenobiotica; 1997 Aug; 27(8):819-29. PubMed ID: 9293618
    [Abstract] [Full Text] [Related]

  • 15. Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats.
    Lin JH, Chen IW, Ulm EH, Duggan DE.
    Drug Metab Dispos; 1988 Aug; 16(3):392-6. PubMed ID: 2900730
    [Abstract] [Full Text] [Related]

  • 16. Clinical pharmacokinetics of the newer ACE inhibitors. A review.
    Kelly JG, O'Malley K.
    Clin Pharmacokinet; 1990 Sep; 19(3):177-96. PubMed ID: 2203579
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles.
    Okuyama CE, Mendes GD, Faro R, Rezende VM, Lagos RM, Astigarraga RE, Antunes E, De Nucci G.
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):290-5. PubMed ID: 17324140
    [Abstract] [Full Text] [Related]

  • 18. The pharmacokinetics of angiotensin converting enzyme inhibitors in patients with renal impairment.
    Begg EJ, Bailey RR, Lynn KL, Robson RA, Frank GJ, Olson SC.
    J Hypertens Suppl; 1989 Sep; 7(5):S29-32. PubMed ID: 2681603
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure.
    Stein G, Sierakowski B, Grass P, Haufe CC, Jansa U, Weidinger G.
    Blood Press Suppl; 1994 Sep; 2():47-53. PubMed ID: 8061846
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin-converting enzyme inhibitors in the therapy of renal diseases.
    Lefebvre HP, Toutain PL.
    J Vet Pharmacol Ther; 2004 Oct; 27(5):265-81. PubMed ID: 15500563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.